secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001493152-24-021628
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PowerUp Acquisition Corp. shareholders approve extension of business combination deadline to Feb 2025
--------------------------------------------------------------------------------

- Shareholders approved extending the deadline to consummate an initial business combination from May 23, 2024 to February 17, 2025.
- Shareholders also approved removing the requirement that the company have at least $5,000,001 in net tangible assets before closing a deal.
- A total of 1,226,085 Class A ordinary shares were redeemed for cash in connection with the meeting.
- Both proposals passed with overwhelming support: Extension 7,753,807 for / 62,254 against; NTA removal 7,816,061 for / 0 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315224021628/0001493152-24-021628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315224021628/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-021628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer